Last reviewed · How we verify
NCT07132528
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer
Phase 4 trial testing SOX plus PD-1 inhibitor in Gastric / Gastroesophageal Junction Adenocarcinoma in 1,000 participants. Not yet recruiting.
31 March 2028
Quick facts
| Lead sponsor | Liaoning Cancer Hospital & Institute |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,000 |
| Start date | 31 August 2025 |
| Primary completion | 31 March 2028 |
| Estimated completion | 30 September 2028 |
Drugs / interventions tested
- SOX plus PD-1 inhibitor — full drug profile →
- SOX Chemotherapy — full drug profile →
Conditions studied
- Gastric / Gastroesophageal Junction Adenocarcinoma — all drugs for Gastric / Gastroesophageal Junction Adenocarcinoma →
Sponsor
Liaoning Cancer Hospital & Institute
Who can join
18 and older, any sex, with Gastric / Gastroesophageal Junction Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to evaluate the efficacy and safety of chemotherapy combined with or without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07132528
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SOX plus PD-1 inhibitor
Trials testing the same drug.
- NCT07161453 — Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinom · Phase 4 · not yet recruiting
- NCT07149181 — Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regim · Phase 4 · not yet recruiting
- NCT06202781 — Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy · unknown
Other recruiting trials for Gastric / Gastroesophageal Junction Adenocarcinoma
Currently open trials in the same condition.
- NCT06406426 — Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and F · Phase 2 · recruiting
Other Liaoning Cancer Hospital & Institute trials
Trials by the same sponsor.
- NCT07161453 — Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinom · Phase 4 · not yet recruiting
- NCT07149181 — Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regim · Phase 4 · not yet recruiting
- NCT06908733 — Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC · Phase 2 · not yet recruiting
- NCT06764251 — Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Ade · Phase 2 · not yet recruiting
- NCT06299371 — Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07132528 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liaoning Cancer Hospital & Institute
- Last refreshed: 20 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07132528.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing